169 related articles for article (PubMed ID: 37953243)
21. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Chang E; Pelosof L; Lemery S; Gong Y; Goldberg KB; Farrell AT; Keegan P; Veeraraghavan J; Wei G; Blumenthal GM; Amiri-Kordestani L; Singh H; Fashoyin-Aje L; Gormley N; Kluetz PG; Pazdur R; Beaver JA; Theoret MR
Oncologist; 2021 Oct; 26(10):e1786-e1799. PubMed ID: 34196068
[TBL] [Abstract][Full Text] [Related]
22. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS.
Kang SL; Woo JH; Kim NH; Kwon JY; Kim SM
Mol Ther Methods Clin Dev; 2023 Sep; 30():447-458. PubMed ID: 37663648
[TBL] [Abstract][Full Text] [Related]
23. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
Tanaka A; Suzuki H; Toyoshima S; Nagai N
Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
[TBL] [Abstract][Full Text] [Related]
24. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.
Batrla R; Jordan BW
Ann N Y Acad Sci; 2015 Jun; 1346(1):71-80. PubMed ID: 25866164
[TBL] [Abstract][Full Text] [Related]
25. The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology.
Dracopoli NC; Boguski MS
Trends Pharmacol Sci; 2017 Jan; 38(1):41-54. PubMed ID: 27789023
[TBL] [Abstract][Full Text] [Related]
26. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
27. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
28. Statistical considerations for some issues in clinical bridging studies evaluating companion diagnostic devices.
Song C; Xiong X; Kim S; Xu Z; Xu D; Biswas B
J Biopharm Stat; 2024 May; 34(3):441-452. PubMed ID: 37330676
[TBL] [Abstract][Full Text] [Related]
29. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
Glorikian H; Warburg RJ; Moore K; Malinowski J
Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
[TBL] [Abstract][Full Text] [Related]
30. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
31. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
32. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
34. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
[TBL] [Abstract][Full Text] [Related]
35. Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics.
Meehan RT; Amigues IA; Knight V
Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441297
[TBL] [Abstract][Full Text] [Related]
36. Statistical consideration and challenges in bridging study of personalized medicine.
Li M
J Biopharm Stat; 2015; 25(3):397-407. PubMed ID: 24897254
[TBL] [Abstract][Full Text] [Related]
37. Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.
Verbaanderd C; Trullás Jimeno A; Engelbergs J; Zander H; Reischl I; Moreno Oliver A; Vamvakas S; Vleminckx C; Bouygues C; Girard T; Day F; Frias Z
Clin Pharmacol Ther; 2023 Aug; 114(2):316-324. PubMed ID: 37132507
[TBL] [Abstract][Full Text] [Related]
38. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation.
Wollenhaupt C; Sudhop T; Knoess W
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370933
[TBL] [Abstract][Full Text] [Related]
39. Emerging biomedical imaging-based companion diagnostics for precision medicine.
Liao S; Zhou M; Wang Y; Lu C; Yin B; Zhang Y; Liu H; Yin X; Song G
iScience; 2023 Aug; 26(8):107277. PubMed ID: 37520706
[TBL] [Abstract][Full Text] [Related]
40. Impact of the new European Union
Hermans AMM; Maliepaard M; Boon WPC; Pasmooij AMG
Expert Rev Mol Diagn; 2022 May; 22(5):583-590. PubMed ID: 35673983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
